Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema
Akrit Sodhi, … , Daoyuan Lu, Silvia Montaner
Akrit Sodhi, … , Daoyuan Lu, Silvia Montaner
Published November 1, 2019; First published September 23, 2019
Citation Information: J Clin Invest. 2019;129(11):4593-4608. https://doi.org/10.1172/JCI120879.
View: Text | PDF
Categories: Research Article Angiogenesis Ophthalmology

Angiopoietin-like 4 binds neuropilins and cooperates with VEGF to induce diabetic macular edema

  • Text
  • PDF
Abstract

The majority of patients with diabetic macular edema (DME), the most common cause of vision loss in working-age Americans, do not respond adequately to current therapies targeting VEGFA. Here, we show that expression of angiopoietin-like 4 (ANGPTL4), a HIF-1–regulated gene product, is increased in the eyes of diabetic mice and patients with DME. We observed that ANGPTL4 and VEGF act synergistically to destabilize the retinal vascular barrier. Interestingly, while ANGPTL4 modestly enhanced tyrosine phosphorylation of VEGF receptor 2, promotion of vascular permeability by ANGPTL4 was independent of this receptor. Instead, we found that ANGPTL4 binds directly to neuropilin 1 (NRP1) and NRP2 on endothelial cells (ECs), leading to rapid activation of the RhoA/ROCK signaling pathway and breakdown of EC-EC junctions. Treatment with a soluble fragment of NRP1 (sNRP1) prevented ANGPTL4 from binding to NRP1 and blocked ANGPTL4-induced activation of RhoA as well as EC permeability in vitro and retinal vascular leakage in diabetic animals in vivo. In addition, sNRP1 reduced the stimulation of EC permeability by aqueous fluid from patients with DME. Collectively, these data identify the ANGPTL4/NRP/RhoA pathway as a therapeutic target for the treatment of DME.

Authors

Akrit Sodhi, Tao Ma, Deepak Menon, Monika Deshpande, Kathleen Jee, Aumreetam Dinabandhu, Jordan Vancel, Daoyuan Lu, Silvia Montaner

×

Figure 3

Upregulation of ANGPTL4 in patients with DME.

Options: View larger image (or click on image) Download as PowerPoint
Upregulation of ANGPTL4 in patients with DME.
(A and B) Levels of ANGPTL...
(A and B) Levels of ANGPTL4 in aqueous samples from nondiabetic (control) patients and diabetic patients with DME who have not previously received anti-VEGF therapy or have not received anti-VEGF therapy for 12 weeks or longer in the sample eye (see Supplemental Table 2) (A) and its correlation with EC permeability. r = –0.8; P < 0.0001 (B). (C and D) ANGPTL4 (C) and VEGF (D) protein levels in DME patients without previous treatment with anti-VEGF therapy (DME Untx) or DME patients who have received a single treatment with anti-VEGF therapy in the sample eye within 6 weeks of sample collection (DME Tx) compared with nondiabetic (control) patients. Mann-Whitney U test (A), Pearson correlation (B), or 1-way ANOVA (C and D). *P < 0.05; **P < 0.01; ****P < 0.0001.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts